Advanced search
Publication Cover
Risk Management and Healthcare Policy Volume 13, 2020 - Issue
Submit an article Journal homepage
199
Views
13
CrossRef citations to date
0
Altmetric
Review

Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic

Nandeeta Samad1 Department of Public Health, North South University, Dhaka1229, BangladeshORCID Iconhttps://orcid.org/0000-0002-3623-0743View further author information
ORCID Icon,
Temitayo Eniola Sodunke2 University of Ilorin, Ilorin, Kwara State, NigeriaORCID Iconhttps://orcid.org/0000-0001-8214-6705View further author information
ORCID Icon,
Hasan Al Banna3 Institute of Social Welfare and Research, University of Dhaka, Dhaka1000, BangladeshORCID Iconhttps://orcid.org/0000-0002-5350-7580View further author information
ORCID Icon,
Ashmita Sapkota4 Department of Microbiology, Mahidol University, Ratchathewi, Bangkok10400, ThailandORCID Iconhttps://orcid.org/0000-0003-3740-0131View further author information
ORCID Icon,
Aneeka Nawar Fatema5 Department of Microbiology, Prima Asia University, Dhaka1213, BangladeshORCID Iconhttps://orcid.org/0000-0001-6206-4470View further author information
ORCID Icon,
Katia Iskandar6 School of Pharmacy, Lebanese University, Beirut, LebanonORCID Iconhttps://orcid.org/0000-0001-5544-6681View further author information
ORCID Icon,
Dilshad Jahan7 Department of Hematology, Asgar Ali Hospital, Dhaka1204, BangladeshORCID Iconhttps://orcid.org/0000-0002-3939-9093View further author information
ORCID Icon,
Timothy Craig Hardcastle8 Department of Surgery, Nelson R Mandela School of Clinical Medicine, University of KwaZulu-Natal, Umbilo, Berea4001, South AfricaORCID Iconhttps://orcid.org/0000-0002-3967-0234View further author information
ORCID Icon,
Tanzina Nusrat9 Department of Microbiology, Chittagong Medical College, Chattogram4203, BangladeshORCID Iconhttps://orcid.org/0000-0001-9434-4661View further author information
ORCID Icon,
Tajkera Sultana Chowdhury10 Department of Urology, Shaheed Suhrawardy Medical College Hospital, Dhaka1207, BangladeshORCID Iconhttps://orcid.org/0000-0001-9482-0031View further author information
ORCID Icon &
Mainul Haque11 Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kuala Lumpur57000, MalaysiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6124-7993View further author information
ORCID Icon show all
Pages 2707-2728 | Published online: 23 Nov 2020

References

  • World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 10 16, 2020 Available from: https://covid19.who.int/. Accessed 1017, 2020.
  • Haque MA, Akram L. Different management strategy of Covid19 patients. Bang J Infect Dis. 2020;7:S51–S53. doi:10.3329/bjid.v7i0.46803
  • Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020:NEJMoa2021436. doi:10.1056/NEJMoa2021436
  • Wong HK, Lee CK. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang. 2020;115(7):545–547. doi:10.1111/vox.1292732240549
  • Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152–157. doi:10.2450/2015.0131-1526674811
  • Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51(2):120–125. doi:10.1016/j.transci.2014.10.003.25457751
  • Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al.; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi:10.1093/infdis/jiu396.25030060
  • Rojas M, Monsalve DM, Pacheco Y, et al. Ebola virus disease: an emerging and re-emerging viral threat. J Autoimmun. 2020;106:102375. doi:10.1016/j.jaut.2019.10237531806422
  • Planitzer CB, Modrof J, Yu MY, Kreil TR. West Nile virus infection in plasma of blood and plasma donors, United States. Emerg Infect Dis. 2009;15(10):1668–1670. doi:10.3201/eid1510.081668.19861071
  • Haley M, Retter A, Fowler D, Gea-Banacloche J, O’Grady N. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis. 2003;37:e88–90. doi:10.1086/377172.12955669
  • Shimoni Z, Niven M, Pitlick S, Bulvik S. Treatment of West Nile Virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis. 2001;7(4):759. doi:10.3201/eid0704.017432.
  • van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for ebola virus disease in guinea. N Engl J Med. 2016;374(1):33–42. doi:10.1056/NEJMoa151181226735992
  • Syal K. COVID-19: herd immunity and convalescent plasma transfer therapy. J Med Virol. 2020;92(9):1380–1382. doi:10.1002/jmv.2587032281679
  • Gayatri R, Lavanya S, Hussain M, Veslin J. The new pandemic Covid-19: treatment options and developments. Asian J Biol. 2020;9(3):1–13. doi:10.9734/AJOB/2020/v9i33008.
  • Corona Tracker. Bangladesh overview. 8 7, 2020 Available from: https://www.coronatracker.com/country/bangladesh/. Accessed 87, 2020.
  • Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554. doi:10.1016/j.autrev.2020.10255432380316
  • Tamburello A, Marando M. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives. Swiss Med Wkly. 2020;150:w20264. doi:10.4414/smw.2020.2026432343358
  • Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. doi:10.1172/JCI138003.32167489
  • Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res. 2000;47(2):57–77. doi:10.1016/s0166-3542(00)00111-x.10996394
  • Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci. 2020;59(3):102794. doi:10.1016/j.transci.2020.102794.32448638
  • Chua Vi Long K, Sayed A, Karki P, Acharya Y. Convalescent blood products in COVID-19: a narrative review. Ther Adv Infect Dis. 2020;7:2049936120960646. doi:10.1177/204993612096064633014364
  • Drexler M Institute of Medicine (US). What you need to know about infectious disease. Washington (DC): National Academies Press (US); 2010 IV, Prevention, and Treatment Available from: https://www.ncbi.nlm.nih.gov/books/NBK209704/. Accessed 1015, 2020.
  • Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73–78. doi:10.4103/0974-777X.77299.21572612
  • Piyush R, Rajarshi K, Khan R, Ray S. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open Biol. 2020;10(9):200174. doi:10.1098/rsob.200174.32898468
  • Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124(4):849–863. doi:10.1016/j.cell.2006.02.019.16497593
  • InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006 How does the immune system work? [Updated April 23, 2020] Available from: https://www.ncbi.nlm.nih.gov/books/NBK279364/. Accessed 1016, 2020.
  • Klimpel GR. Immune defenses In: Baron S, editor. Medical Microbiology. 4th edition ed. Galveston: University of Texas Medical Branch at Galveston; 1996 Chapter 50 Available from: https://www.ncbi.nlm.nih.gov/books/NBK8423/. Accessed 1016, 2020.
  • Nicholson LB. The immune system. Essays Biochem. 2016;60(3):275–301. doi:10.1042/EBC2016001727784777
  • Raab CP. Passive immunization. Prim Care. 2011;38(4):681–91, viii. doi:10.1016/j.pop.2011.07.006.22094139
  • Slifka MK, Amanna IJ. Passive immunization. Plotkin’s Vaccines. 2018;84–95. e10. doi:10.1016/B978-0-323-35761-6.00008-0
  • Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS. 2015;10(3):129–134. doi:10.1097/COH.000000000000015425760933
  • Hey A. History and practice: antibodies in infectious diseases. Microbiol Spectr. 2015;3(2):AID-0026-2014 PMID: 26104697. doi:10.1128/microbiolspec.AID-0026-2014.
  • Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–161. doi:10.1093/clinids/21.1.150.7578724
  • Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703. doi:10.1038/nrmicro974.15372080
  • Bracha A, Tan SY. Emil von Behring (1854–1917): medicine’s first Nobel laureate. Singapore Med J. 2011;52(1):1–2. PMID: 21298232.21298232
  • Winau F, Winau R. Emil von Behring, and serum therapy. Microbes Infect. 2002;4(2):185–188. doi:10.1016/s1286-4579(01)01526-x.11880051
  • Behring E, Kitasato S. Über das Zustandekommen der DiphtherieImmunität und der Tetanus-Immunität bei Thieren [On the development of immunity to diphtheria and tetanus in animals]. Dtsch Med Wochenschr. 1890;16:1113–1114. doi:10.1055/s-0029-1207589
  • Pucca MB, Cerni FA, Janke R, et al. History of envenoming therapy and current perspectives. Front Immunol. 2019;10:1598. doi:10.3389/fimmu.2019.01598.31354735
  • Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995;171(6):1387–1398. doi:10.1093/infdis/171.6.1387.7769272
  • Beigel JH, Voell J, Kumar P, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a Phase 1 randomized, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018;18(4):410–418. doi:10.1016/S1473-3099(18)30002-1.29329957
  • Shamim S, Khan M, Kharaba ZJ, Ijaz M, Murtaza G. Potential strategies for combating COVID-19. Arch Virol. 2020;165(11):2419–2438. doi:10.1007/s00705-020-04768-332778950
  • Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003;24(9):474–478. doi:10.1016/s1471-4906(03)00228-x.12967670
  • Forthal DN. Functions of Antibodies. Microbiol Spectr. 2014;2(4):1–17.
  • The World Bank. The Global Economic Outlook during the COVID-19 pandemic: a changed world; 2020 Available from: https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world. Accessed 731, 2020.
  • Anwar S, Nasrullah M, Hosen MJ. COVID-19 and Bangladesh: challenges and how to address them. Front Public Health. 2020;8:154. doi:10.3389/fpubh.2020.0015432426318
  • WORLDOMETER. COVID-19 Coronavirus Pandemic; 2020 Available from: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?%22. Accessed 731, 2020.
  • Ritchie H, Ortiz-Ospina E, Beltekian D, et al. Coronavirus Pandemic (COVID-19) – the data; 2020 Available from: https://ourworldindata.org/coronavirus-data. Accessed 731, 2020.
  • Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Jul 4] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed 81, 2020.
  • Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the recent 2019 novel Coronavirus (SARS-CoV-2) in light of past human Coronavirus outbreaks. Pathogens. 2020;9(3):186. doi:10.3390/pathogens9030186
  • Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–2019. doi:10.26355/eurrev_202002_2037932141570
  • Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, et al. Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. Travel Med Infect Dis. 2020;35:101653. doi:10.1016/j.tmaid.2020.10165332247926
  • Jiang S. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020;579(7799):321. doi:10.1038/d41586-020-00751-932179860
  • Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–1766. doi:10.7150/ijbs.4513432226295
  • Mas-Coma S, Jones MK, Marty AM. COVID-19 and globalization. One Health. 2020;9:100132. doi:10.1016/j.onehlt.2020.10013232368611
  • Shadmi E, Chen Y, Dourado I, et al. Health equity and COVID-19: global perspectives. Int J Equity Health. 2020;19(1):104. doi:10.1186/s12939-020-01218-z32586388
  • Wang Z, Tang K. Combating COVID-19: health equity matters. Nat Med. 2020;26(4):458. doi:10.1038/s41591-020-0823-632284617
  • Ramirez-Valles J, Breton E, Chae DH, Haardörfer R, Kuhns LM. The COVID-19 pandemic: everything old is new again in public health education. Health Educ Behav. 2020;47(4):501–503. doi:10.1177/109019812093506732517520
  • Ali S, Asaria M, Stranges S. COVID-19, and inequality: are we all in this together? Can J Public Health. 2020;111(3):415–416. doi:10.17269/s41997-020-00351-032578185
  • Milne A UK under fire for suggesting coronavirus ‘great leveler.’ Reuters; 2020 Available from: https://www.reuters.com/article/us-health-coronavirus-leveller-trfn/uk-under-fire-for-suggesting-coronavirus-great-leveller-idUSKCN21R30P. Accessed 81, 2020.
  • McGreal C The inequality virus: how the pandemic hit America’s poorest. The Guardian; 2020 Available from: https://www.theguardian.com/world/2020/apr/09/america-inequality-laid-bare-coronavirus. Accessed 81, 2020.
  • Nakamura K, Hikone M, Shimizu H, et al. A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: a case report. J Infect Chemother. 2020;26(7):756–761. doi:10.1016/j.jiac.2020.03.01832317225
  • Zeng Y, Cai Z, Xianyu Y, Yang BX, Song T, Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care. 2020;24(1):148. doi:10.1186/s13054-020-2840-832293518
  • Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–e18. doi:10.1016/j.jinf.2020.03.005
  • Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med. 2020:1–8. doi:10.1007/s42399-020-00363-4.
  • Gholipour C, Rad BS, Vahdati SS, Ghaffarzad A, Masoud A. Evaluation of preventable trauma death in emergency department of Imam Reza hospital. World J Emerg Med. 2016;7(2):135–137. doi:10.5847/wjem.j.1920-8642.2016.02.00927313809
  • Eastridge BJ, Holcomb JB, Shackelford S. Outcomes of traumatic hemorrhagic shock and the epidemiology of preventable death from injury. Transfusion. 2019;59(S2):1423–1428. doi:10.1111/trf.1516130980749
  • Barelli S, Alberio L. The role of plasma transfusion in massive bleeding: protecting the endothelial glycocalyx? Front Med (Lausanne). 2018;5:91. doi:10.3389/fmed.2018.0009129721496
  • Simmons JW, Pittet JF, Pierce B. Trauma-Induced Coagulopathy. Curr Anesthesiol Rep. 2014;4(3):189–199. doi:10.1007/s40140-014-0063-825587242
  • Nair PM, Rendo MJ, Reddoch-Cardenas KM, Burris JK, Meledeo MA, Cap AP. Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. Semin Hematol. 2020;57(2):73–82. doi:10.1053/j.seminhematol.2020.07.00632892846
  • Gokhale SG, Scorer T, Doughty H. Freedom from frozen: the first British military use of lyophilized plasma in forward resuscitation. J R Army Med Corps. 2016;162(1):63–65. doi:10.1136/jramc-2014-00036125535320
  • Inaba K. Freeze-dried plasma. J Trauma. 2011;70(5 Suppl):S57–S58. doi:10.1097/TA.0b013e31821a605721841576
  • Sridevi K, Munjal A, Chandran A, et al. Convalescent plasma therapy for prophylaxis and treatment of COVID-19: a systematic research of facts and files, a narrative review. Ann Clin Lab Res. 2020;8(2):314.
  • The American Society for Microbiology. The toxin-based diseases common in North America during the 1600-1700s; 2019 Available from: https://asm.org/Articles/2019/July/The-Toxin-Based-Diseases-Common-in-North-America-d. Accessed 81, 2020.
  • Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion. 2010;50(6):1384–1398. doi:10.1111/j.1537-2995.2010.02590.x20158681
  • WHO Mers-Cov Research Group. State of knowledge and data gaps of middle east respiratory syndrome Coronavirus (MERS-CoV) in Humans. PLoS Curr. 2013;5:ecurrents. outbreaks. doi:10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
  • Zingher A, Mortimer P. Convalescent whole blood, plasma, and serum in the prophylaxis of measles: JAMA, 12 April 1926; 1180-1187. Rev Med Virol. 2005;15(6):407–421. doi:10.1002/rmv.48016211552
  • Young MK, Nimmo GR, Cripps AW, Jones MA. ost-exposure passive immunization for preventing measles. Cochrane Database Syst Rev. 2014;4:CD010056. doi:10.1002/14651858.CD010056.pub2
  • Beigel JH, Luke TC. A study in scarlet-convalescent plasma for severe influenza*. Crit Care Med. 2012;40(3):1027–1028. doi:10.1097/CCM.0b013e31823d77c322343871
  • Montelongo-Jauregui D, Vila T, Sultan AS, Jabra-Rizk MA. Convalescent serum therapy for COVID-19: a 19th-century remedy for a 21st-century disease. PLoS Pathog. 2020;16(8):e1008735. doi:10.1371/journal.ppat.100873532785259
  • Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. doi:10.1172/JCI13874532254064
  • Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496. doi:10.1073/pnas.200416811732253318
  • Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020;323(16):1582–1589. doi:10.1001/jama.2020.478332219428
  • Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: a Randomized Clinical Trial. JAMA. 2020;324(5):460–470. doi:10.1001/jama.2020.1004432492084
  • Langhi DM Jr, Santis GC, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther. 2020;42(2):113–115. doi:10.1016/j.htct.2020.04.00332313872
  • Diep BA, Le VT, Badiou C, et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med. 2016;8(357):357ra124. doi:10.1126/scitranslmed.ag1153
  • Luke T, Casadevall A, Watowich S, Hoffman S, Beigel J, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38(4 suppl):e66–e73. doi:10.1097/CCM.0b013e3181d44c1e20154602
  • Al-Riyami AZ, Schäfer R, van der Berg K, et al. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focused gap analysis with recommendations for future research priorities. Vox Sang. 2020. doi:10.1111/vox.12973
  • Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256. doi:10.1136/bmj.m125632217555
  • Zhang L, Pang R, Xue X, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY). 2020;12(8):6536–6542. doi:10.18632/aging.10310232320384
  • Kumar GV, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect. 2020;35:100682. doi:10.1016/j.nmni.2020.10068232313660
  • Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. N Engl J Med. 2016;374(7):636–646. doi:10.1056/NEJMoa150487426886522
  • Kraft CS, Hewlett AL, Koepsell S, et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients with Ebola Virus Disease in the United States. Clin Infect Dis. 2015;61(4):496–502. doi:10.1093/cid/civ33425904375
  • Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-9s32113510
  • Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020. doi:10.1002/jmv.25882
  • Cheng Y, Wong R, Soo YO. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46. doi:10.1007/s10096-004-1271-915616839
  • Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676–678. doi:10.1111/j.1469-0691.2004.00956.x15214887
  • Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609. doi:10.7326/0003-4819-145-8-200610170-0013916940336
  • MacLennan S, Barbara JA. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol. 2006;19(1):169–189. doi:10.1016/j.beha.2005.01.03316377549
  • Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. 2020. doi:10.1111/vox.12939
  • Hardcastle TC. Complications of massive transfusion in trauma patients. ISBT Sci Ser. 2006;1:180–184. doi:10.1111/j.1751-2824.2006.00027.x
  • Malani AN, Sherbeck JP, Malani PN. Convalescent Plasma and COVID-19. JAMA. 2020;324(5):524. doi:10.1001/jama.2020.1069932530454
  • Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020. doi:10.1002/jmv.25961
  • van Griensven J, Edwards T, Baize S; Ebola-Tx Consortium. Efficacy of convalescent plasma in relation to dose of ebola virus antibodies. N Engl J Med. 2016;375(23):2307–2309. doi:10.1056/NEJMc1609116
  • Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. doi:10.3346/jkms.2020.35.e14932281317
  • Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically Ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158(1):e9–e13. doi:10.1016/j.chest.2020.03.03932243945
  • Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59–73. doi:10.1016/j.bbi.2020.04.04632334062
  • Devasenapathy N, Ye Z, Loeb M, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. CMAJ. 2020;192(27):E745–E755. doi:10.1503/cmaj.20064232444482
  • Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020;115(6):488–494. doi:10.1111/vox.1292632240545
  • Barone P, DeSimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion. 2020;60(6):1123–1127. doi:10.1111/trf.1584332374891
  • Casadevall A, Joyner MJ, Pirofski LA. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA. 2020;324(5):455–457. doi:10.1001/jama.2020.1021832492105
  • Bloch EM. Convalescent plasma to treat COVID-19. Blood. 2020;136(6):654–655. PMID: 32761219; PMCID: PMC7414591. doi:10.1182/blood.2020007714.32761219
  • Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791–4797. PMID: 32525844; PMCID: PMC7456238. doi:10.1172/JCI140200.32525844
  • Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59(3):102790 PMID: 32345485; PMCID: PMC7194745. doi:10.1016/j.transci.2020.102790.32345485
  • Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888–1897. doi:10.1016/j.mayocp.2020.06.02832861333
  • Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26(10):1436–1446. doi:10.1016/j.cmi.2020.08.00532791241
  • US National Library of Medicine. ClinicalTrails.gov. COVID-19 studies from the World Health Organization Database; 2020 Available from: https://clinicaltrials.gov/ct2/who_table. Accessed 1017, 2020.
  • Verma HK, Merchant N, Verma MK, et al. Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19). Biomed J. 2020;S2319-4170(20)30127-X. doi:10.1016/j.bj.2020.07.008
  • Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med. 2020;38(7):1488–1493. doi:10.1016/j.ajem.2020.04.03532336586
  • Montravers P, de Tymowski C, Assadi M, Yung S, Kantor E. Just a little bit more patience …. Anaesth Crit Care Pain Med. 2020;39(3):383–384. doi:10.1016/j.accpm.2020.05.00432405519
  • US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma; 2020 Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma#:~:text=Because%20convalescent%20plasma%20for%20the,plasma%20or%20provide%20convalescent%20plasma. Accessed 1017, 2020.
  • U.S. Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma, s.l.: FDA; 2020 Available from: www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed July 27, 2020.
  • Frazier SK, Higgins J, Bugajski A, Jones AR, Brown MR. Adverse reactions to transfusion of blood products and best practices for prevention. Crit Care Nurs Clin North Am. 2017;29(3):271–290. doi:10.1016/j.cnc.2017.04.00228778288
  • Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: possibilities and Challenges. JAMA. 2020;323(16):1561. doi:10.1001/jama.2020.494032219429
  • Seifried E, Schmidt M. Transfusion‐transmitted virus infections (TTVIs). Part V: hazards of transfusion. Chapter 51 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:581–598.
  • Spenser BR. Transfusion transmission of parasites. Part V: hazards of transfusion. Chapter 52 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:599–607.
  • Benjamin RJ. Bacterial contamination of blood components. Part V: hazards of transfusion. Chapter 53 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:608–619.
  • Pham TD, Galel SA. Testing for pathogens in donors. Part V: hazards of transfusion. Chapter 53 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:626–631.
  • Maskens C, Downie H, Wendt A, et al. Hospital-based transfusion error tracking from 2005 to 2010: identifying the key errors threatening patient transfusion safety. Transfusion. 2014;54(1):65–66. doi:10.1111/trf.12240
  • Crookston KP, Koenig SC, Reyes MD. Transfusion reaction identification and management at the bedside. J Infus Nurs. 2015;38(2):104–113. doi:10.1097/NAN.000000000000009725723832
  • Pérez-Cameo C, Marín-Lahoz J. Serosurveys and convalescent plasma in COVID-19. E Clin Med. 2020;23:100370. doi:10.1016/j.eclinm.2020.100370
  • Chaurasia R, Zaman S, Das B, Chatterjee K. Screening donated blood for transfusion transmitted infections by serology along with NAT and response rate to notification of reactive results: an indian experience. J Blood Transfus. 2014;2014:412105. doi:10.1155/2014/41210525485163
  • Allain JP, Goodrich R. Pathogen reduction of whole blood: utility and feasibility. Transfus Med. 2017;27(Suppl 5):320–326. doi:10.1111/tme.1245628875531
  • Eder A, Goldman M, Rossmann S, Waxman D, Bianco C. Selection criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence), and future (hemovigilance). Transfus Med Rev. 2009;23(3):205–220. doi:10.1016/j.tmrv.2009.03.00319539875
  • World Health Organization. How to safely collect blood samples from persons suspected to be infected with highly infectious blood-borne pathogens. (e.g., Ebola), s.l.: WHO; 2014 Available from: euro.who.int/en/health-topics/health-emergencies/ebola-outbreak-2014/technical-information/laboratory/how-to-safely-collect-blood-samples-from-persons-suspected-to-be-infected-with-highly-infectious-blood-borne-pathogens-e.g.-ebola. Accessed 726, 2014.
  • Triulzi DJ, Yazer MH, Waters JH. Patient blood management. Part I: contemporary issues in donation and transfusion. Chapter 2 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:11–22.
  • Gehrie EA, Chandler J, Snyder EL. Clinical and technical aspects of blood administration. Part I: contemporary issues in donation and transfusion. Chapter 3 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:23–29.
  • Crookston KP, Pritchard AE, Simon TL. Recruitment and screening of donors and the collection, processing, and testing of blood. Part I: contemporary issues in donation and transfusion. Chapter 4 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:30–42.
  • Flesland Ø, Wiersum‐Osselton JC. Donor vigilance and hemovigilance. Part I: contemporary issues in donation and transfusion. Chapter 6 In: Simon TL, McCullough J, Snyder EL, Solheim BG, Ronald GS, editors. Rossi’s Principles of Transfusion Medicine. 5th ed. 9600 Garsington Rd, Cowley, Oxford OX4 2DQ, UK: John Willey and Sons, Ltd; 2016:58–68.
  • U.S. Food and Drug Administration. Investigational COVID-19 Convalescent Plasma Guidance for Industry, S.l.: FDA; 2020 Available from: www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-covid-19-convalescent-plasma. Accessed 277 2020.
  • World Health Organization. ‎Blood donor selection: guidelines on assessing donor suitability for blood donation. World Health Organization; 2012 Available from: https://apps.who.int/iris/handle/10665/76724. Accessed 731, 2020.
  • World Health Organization. ‎Ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic: interim guidance for ethics review committees, researchers, national health authorities, and blood transfusion services. World Health Organization; 2015 Available from: https://apps.who.int/iris/handle/10665/161912. Accessed 731, 2020.
  • World Health Organization. ‎Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services, Version 1.0 September 2014. World Health Organization; 2014 Available from: https://apps.who.int/iris/handle/10665/135591. Accessed 731, 2020.
  • Anudeep TC, Jeyaraman M, Shetty DU, et al. Convalescent plasma as a plausible therapeutic option in nCOVID-19: a review. J Clin Trials. 2020;10:409. doi:10.35248/2167-0870.20.10.409
  • Cai X, Ren M, Chen F, Li L, Lei H, Wang X. Blood transfusion during the COVID-19 outbreak. Blood Transfus. 2020;18(2):79–82. doi:10.2450/2020.0076-2032267830
  • Shammi M, Bodrud-Doza M, Towfiqul Islam ARM, Rahman MM. COVID-19 pandemic, socioeconomic crisis, and human stress in resource-limited settings: a case from Bangladesh. Heliyon. 2020;6(5):e04063. doi:10.1016/j.heliyon.2020.e0406332462098
  • Haque M, Islam S, Iqbal S, et al. Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. Bang J Med Sci. 2020;19(Special Issue COVID–19):S366–SS50. doi:10.3329/bjms.v19i0.48106
  • Hossain MI Covid-19: Bangladesh also exploring plasma therapy as a ray of hope. United News of Bangladesh; 2020 Available from: https://unb.com.bd/category/Special/covid-19-bangladesh-also-exploring-plasma-therapy-as-a-ray-of-hope/52015. Accessed 71, 2020.
  • Skrip L, Derra K, Kabore M, et al. Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis. medRxiv. 2020. doi:10.1101/2020.06.04.20119784
  • Pei S, Yuan X, Zhang Z, et al. Convalescent plasma to treat COVID-19: Chinese strategy and experiences. medRxiv. 2020. doi:10.1101/2020.04.07.20056440
  • Haque M High cost of COVID-19 test at Pvt hospitals raises concerns United News of Bangladesh; 2020 Available from: http://unb.com.bd/category/Special/high-cost-of-covid-19-test-at-pvt-hospitals-raises-concern/53389. Accessed 72, 2020.
  • Ahmed W Treatment denied at hospitals. The Financial Express; 2020 https://thefinancialexpress.com.bd/views/treatment-denied-at-hospitals-1589902122. Accessed 72, 2020.
  • Tajmim T Private hospitals unable, unwilling to treat coronavirus patients. The Business Standard; 2020 Available from: https://tbsnews.net/bangladesh/health/private-hospitals-unable-unwilling-treat-coronavirus-patients-54169. Accessed 731, 2020.
  • Center for Policy Dialogue (CPD). Corona pandemic and Bangladesh: health and economic risks and recommendations. Working Paper-133; 2020 Available from: cpd.org.bd/wp-content/uploads/2020/04/CPD-Working-Paper-133-Corona-Pandemic-and-Bangladesh-Health-and-Economic-Risks-and-Recommendations.pdf. Accessed 72¸2020.
  • Lee P, Hsueh P. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53(3):365–367. doi:10.1016/j.jmii.2020.02.00132035811
  • US Food and Drug Administration. Donate COVID-19 plasma; 2020 Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma. Accessed 731, 2020.
  • Mayo Clinic. COVID-19 expanded access program. Plasma donors needed for treatment protocol. 200 First St. SW Rochester, MN 55905, USA; 2020 Available from: https://www.uscovidplasma.org/. Accessed 731, 2020.
  • Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38–43. doi:10.1093/infdis/jiaa22832348485
  • Xia X, Li K, Wu L, et al. Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood. 2020;136(6):755–759. doi:10.1182/blood.202000707932573724
  • Vieillard V, Astier A, Sauzay C, Paul M. One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4°C and 25°C. Ann Pharm Fr. 2017;75(1):17–29. doi:10.1016/j.pharma.2016.08.00227659414
  • González-García J, Gutiérrez-Nicolás F, Nazco-Casariego GJ, Viña-Romero MM. Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions [Estabilidad a largo plazo del trastuzumab en plasma y suero almacenados bajo diferentes condiciones]. Farm Hosp. 2019;43(2):50–52. doi:10.7399/fh.1111030848176
  • Stadlbauer D, Baine I, Amanat F, et al. Anti-SARS-CoV2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks. Transfusion. 2020;60(10):2457–2459. doi:10.1111/trf.16047
  • Tonn T, Corman VM, Johnsen M, et al. Stability and neutralizing capacity of SARS-CoV-2-specific antibodies in convalescent plasma. Lancet Microbe. 2020;1(2):e63. doi:10.1016/S2666-5247(20)30037-932835332
  • Vanderwerf JD, Kumar MA. Management of neurologic complications of coagulopathies. Handb Clin Neurol. 2017;141:743–764. doi:10.1016/B978-0-444-63599-0.00040-528190445
  • Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358–1364. doi:10.1097/CCM.000000000000445832467443
  • Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103–2109. doi:10.1111/jth.14975
  • Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149. doi:10.1177/107602962093814932677459
  • Aggarwal M, Dass J, Mahapatra M. Hemostatic abnormalities in COVID-19: an update. Indian J Hematol Blood Transfus. 2020;1–11. doi:10.1007/s12288-020-01328-2
  • Levi M. COVID-19 coagulopathy vs. disseminated intravascular coagulation. Blood Adv. 2020;4(12):2850. doi:10.1182/bloodadvances.202000219732574369
  • Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–847. doi:10.1002/ajh.2582932282949
  • Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin Rheumatol. 2020;39(9):2529–2543. doi:10.1007/s10067-020-05275-132654082
  • Yu HH, Qin C, Chen M, Wang W, Tian DS. The D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195:219–225. doi:10.1016/j.thromres.2020.07.04732777639
  • Becker RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54–67. doi:10.1007/s11239-020-02134-332415579
  • Garraud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23(1):39–44. doi:10.1016/j.tracli.2015.12.00326775794
  • Luczkowiak J, Arribas JR, Gómez S, et al. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Res. 2016;213:224–229. doi:10.1016/j.virusres.2015.12.01926739425
  • Luczkowiak J, Lasala F, Mora-Rillo M, Arribas JR, Delgado R. Broad neutralizing activity against ebolaviruses lacking the mucin-like domain in convalescent plasma specimens from patients with ebola virus disease. J Infect Dis. 2018;218(suppl_5):S574–S581. doi:10.1093/infdis/jiy30229939289
  • Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology - mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89. doi:10.1038/nrneurol.2014.25325561275
  • Bilgin YM, Brand A. Transfusion-related immunomodulation: a second hit in an inflammatory cascade? Vox Sang. 2008;95(4):261–271. doi:10.1111/j.1423-0410.2008.01100.x19138255
  • Refaai MA, Blumberg N. Transfusion immunomodulation from a clinical perspective: an update. Expert Rev Hematol. 2013;6(6):653–663. doi:10.1586/17474086.2013.85002624168641
  • Wang Y, Zhang Y, Yu Q, Zhu K. Convalescent plasma coupled with medications for the treatment of a severe covid-19 patient: drugs analysis and pharmaceutical care based on the newly established guidelines for COVID-19 remedy. Front Pharmacol. 2020;11:966. doi:10.3389/fphar.2020.0096632670071
  • Psaltopoulou T, Sergentanis TN, Pappa V, et al. The emerging role of convalescent plasma in the treatment of COVID-19. Hemasphere. 2020;4(3):e409. doi:10.1097/HS9.000000000000040932647807
  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239. doi:10.1001/jama.2020.264832091533
  • Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sci. 2020;258:118185. doi:10.1016/j.lfs.2020.118185s32750438
  • Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718–1723. doi:10.7150/ijbs.45123432226289
  • Sharun K, Tiwari R, Iqbal Yatoo M, et al. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. Expert Opin Biol Ther. 2020;20(9):1033–1046. doi:10.1080/14712598.2020.179696332744917
  • Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15(1):192. doi:10.1186/s12985-018-1105-530587193
  • Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005;56(5):919–922. doi:10.1093/jac/dki34616183666
  • van Griensven J, Edwards T, Gallian P; Ebola-Tx Consortium. Convalescent plasma for ebola virus disease. N Engl J Med. 2016;374(25):2500. doi:10.1056/NEJMc160228427332913
  • Accorsi P, Berti P, de Angelis V, De Silvestro G, Mascaretti L, Ostuni A; Italian Society for Transfusion Medicine Immunohaematology (SIMTI) Italian Society for Hemapheresis cell Manipulation (SIdEM). Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus Apher Sci. 2020;59(4):102817. doi:10.1016/j.transci.2020.10281732532691
  • Anand SP, Finzi A. Understudied factors influencing Fc-Mediated immune responses against viral infections. Vaccines (Basel). 2019;7(3):103. doi:10.3390/vaccines7030103
  • Lewis GK, Pazgier M, Evans DT, et al. Beyond viral neutralization. AIDS Res Hum Retroviruses. 2017;33(8):760–764. doi:10.1089/AID.2016.029928084796
  • Salazar E, Perez KK, Ashraf M, et al. Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. Am J Pathol. 2020;190(8):1680–1690. doi:10.1016/j.ajpath.2020.05.01432473109
  • Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–614. doi:10.1128/cmr.13.4.602-614.200011023960
  • Eyler JM. The state of science, microbiology, and vaccines circa 1918. Public Health Rep. 2010;125(Suppl 3):27–36. doi:10.1177/00333549101250S30620568567
  • Berry CM. Antibody immunoprophylaxis and immunotherapy for influenza virus infection: utilization of monoclonal or polyclonal antibodies? Hum Vaccin Immunother. 2018;14(3):796–799. doi:10.1080/21645515.2017.136313528854120
  • Annamaria P, Eugenia Q, Paolo S. Anti-SARS-CoV-2 hyperimmune plasma workflow. Transfus Apher Sci. 2020;102850. doi:10.1016/j.transci.2020.10285032540345
  • Kreil TR, Mc Vey JK, Lei LS, et al. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza. Transfusion. 2012;52(4):803–809. doi:10.1111/j.1537-2995.2011.03347.x21981280
  • Young MK. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella, and measles. Hum Vaccin Immunother. 2019;15(9):2060–2065. doi:10.1080/21645515.2019.162114831116633
  • Fleurant-Ceelen A, Tunis M, House A. What is new in the Canadian immunization Guide: November 2016 to November 2018. Can Commun Dis Rep. 2018;44(12):331–335. doi:10.14745/ccdr.v44i12a0631517951
  • Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: recommendations of the advisory committee on immunization practices for use of Hepatitis A Vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel. MMWR Morb Mortal Wkly Rep. 2018;67(43):1216–1220. doi:10.15585/mmwr.mm6743a530383742
  • Khadka S, Yuchi A, Shrestha DB, et al. Repurposing Drugs for COVID-19: an Approach for Treatment in the Pandemic. Altern Ther Health Med. 2020:AT6513.32827400
  • Hachfi W, Ben Lasfar N. COVID-19: main therapeutic options. Tunis Med. 2020;98(4):299–303.32395792
  • Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113–119. doi:10.1038/s41586-020-2577-132707573
  • Haque M. The COVID-19 pandemic - a global public health crisis: a brief overview regarding pharmacological interventions. Pesqui Bras Odontopediatria Clín Integr. 2020;20(Suppl 1):e0146. doi:10.1590/pboci.2020.137
  • Estcourt LJ, Roberts DJ. Convalescent plasma for covid-19. BMJ. 2020;370:m3516. doi:10.1136/bmj.m351632933945
  • Mahase E. Covid-19: US approves emergency use of convalescent plasma despite warnings over lack of evidence. BMJ. 2020;370:m3327. doi:10.1136/bmj.m332732843328
  • Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7(7):CD013600. doi:10.1002/14651858.CD013600.pub232648959
  • Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):499. doi:10.1186/s13063-020-04422-y32513308
  • Bobek I, Gopcsa L, Réti M, et al. Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases. [Az első két sikeres, convalescens friss fagyasztott plazmával történő terápia hazai alkalmazása intenzív osztályon kezelt, kritikus állapotú, COVID–19-fertőzésben szenvedő betegekben: (A COVID–19-pandémia orvosszakmai kérdései)]. Orv Hetil. 2020;161(27):1111–1121. PMID: 32564002. doi:10.1556/650.2020.31901.32564002
  • Zeng H, Wang D, Nie J, et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther. 2020;5(1):219. doi:10.1038/s41392-020-00329-x33024082
  • Li L, Yang R, Wang J, et al. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Transfusion. 2020;60(8):1773–1777. doi:10.1111/trf.1592132491199
  • Kong Y, Cai C, Ling L, et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. Transfus Apher Sci. 2020;102820. doi:10.1016/j.transci.2020.10282032467007
  • Bloch EM, Goel R, Montemayor C, Cohn C, Tobian AAR. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries. Transfus Apher Sci. 2020;102957. doi:10.1016/j.transci.2020.10295732972861
  • Verhagen LM, de Groot R, Lawrence CA, Taljaard J, Cotton MF, Rabie H. COVID-19 response in low- and middle-income countries: don’t overlook the role of mobile phone communication. Int J Infect Dis. 2020;99:334–337. doi:10.1016/j.ijid.2020.07.06932763447
  • Bloch EM, Goel R, Wendel S, et al. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. Vox Sang. 2020. doi:10.1111/vox.12970
  • Weimer A, Tagny CT, Tapko JB, et al. Blood transfusion safety in sub-Saharan Africa: a literature review of changes and challenges in the 21st century. Transfusion. 2019;59(1):412–427. doi:10.1111/trf.1494930615810
  • Ware AD, Jacquot C, Tobian AAR, Gehrie EA, Ness PM, Bloch EM. Pathogen reduction and blood transfusion safety in Africa: strengths, limitations, and challenges of implementation in low-resource settings. Vox Sang. 2018;113(1):3–12. doi:10.1111/vox.1262029193128
  • Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tayou Tagny C, Bloch EM. The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. Transfus Med Rev. 2015;29(1):35–44. doi:10.1016/j.tmrv.2014.09.003.2544755525447555
  • Ferreira LMR, Mostajo-Radji MA. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic. NPJ Vaccines. 2020;5:58. doi:10.1038/s41541-020-0209-232655899
  • Epstein J, Smid WM, Wendel S, Somuah D, Burnouf T. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety. Vox Sang. 2020. doi:10.1111/vox.12964
  • Alabdulmonem W, Shariq A, Rasheed Z. COVID-19: a global public health disaster. Int J Health Sci (Qassim). 2020;14(3):7–8.32536842
  • Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat. J Infect Public Health. 2020;13(4):644–646. doi:10.1016/j.jiph.2020.02.03332199792
  • Contini C, Di Nuzzo M, Barp N, et al. The novel zoonotic COVID-19 pandemic: an expected global health concern. J Infect Dev Ctries. 2020;14(3):254–264. doi:10.3855/jidc.1267132235085
  • Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): a Review. JAMA. 2020. doi:10.1001/jama.2020.6019
  • Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443. doi:10.1016/j.jmii.2020.03.03432307245
  • Verma HK, Farran B, Bhaskar LVKS. Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates. Antibody Ther. 2020;3(2):115–125. doi:10.1093/abt/tbaa010
  • Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56(2):106054. doi:10.1016/j.ijantimicag.2020.10605432534188
  • Zhao Q, He Y. Challenges of Convalescent Plasma Therapy on COVID-19. J Clin Virol. 2020;127:104358. doi:10.1016/j.jcv.2020.10435832305026
  • Saadah NH, van Hout FMA, Schipperus MR, et al. Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression. Transfusion. 2017;57(9):2104–2114. doi:10.1111/trf.1424528766723
  • Accorsi P, Berti P, de Angelis V, De Silvestro G, Mascaretti L, Ostuni A; Italian Society for Transfusion Medicine and Immunohaematology (SIMTI) and the Italian Society for Haemapheresis and Cell Manipulation (SIdEM). Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Blood Transfus. 2020;18(3):163–166. doi:10.2450/2020.0124-2032453687
  • Franchini M. Why should we use convalescent plasma for COVID-19? Eur J Intern Med. 2020;77:150–151. doi:10.1016/j.ejim.2020.05.01932425365
  • World O Meter. COVID-19 Coronavirus Pandemic; 2020 Available from: https://www.worldometers.info/coronavirus/?fbclid=IwAR2UgycDn8i64zB71xUGm5svanZxQEI_U6IEEzgiNRtMnVLtBQtyKqPW_e8. Accessed 1018, 2020.
  • World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19-11 March 2020; 2020 Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020., Accessed 87, 2020.
  • Rust G, Melbourne M, Truman BI, Daniels E, Fry-Johnson Y, Curtin T. Role of the primary care safety net in pandemic influenza. Am J Public Health. 2009;99(Suppl2):S316–S323. doi:10.2105/AJPH.2009.16112519797743
  • Kunin M, Engelhard D, Thomas S, Ashworth M, Piterman L. Challenges of the pandemic response in primary care during pre-vaccination period: a qualitative study. Isr J Health Policy Res. 2015;4:32. doi:10.1186/s13584-015-0028-526473026
  • Desborough J, Hall Dykgraaf S, Rankin D, Kidd M. The importance of consistent advice during a pandemic: an analysis of Australian advice regarding personal protective equipment in healthcare settings during COVID-19. Aust J Gen Pract. 2020;49(6):369–372. doi:10.31128/AJGP-04-20-537432464735
  • Desborough J, Hall Dykgraaf S, de Toca L, et al. Australia’s national COVID-19 primary care response. Med J Aust. 2020;213(3):104–106.e1. doi:10.5694/mja2.5069332623740
  • Sarti TD, Lazarini WS, Fontenelle LF, Almeida APSC. What is the role of Primary Health Care in the COVID-19 pandemic? Epidemiologia e Serviços De Saúde. 2020;29(2):e2020166. doi:10.5123/s1679-4974202000020002432348404
  • World Health Organization. WHO statement on cases of COVID-19 surpassing 100 000; 2020 Available from: https://www.who.int/news-room/detail/07-03-2020-who-statement-on-cases-of-covid-19-surpassing-100-000. Accessed 87, 2020.
  • Legido-Quigley H, Asgari N, Teo YY, et al. Are high-performing health systems resilient against the COVID-19 epidemic? Lancet. 2020;395(10227):848–850. doi:10.1016/S0140-6736(20)30551-132151326
  • Chang BB, Chiu TY. Ready for a long fight against the COVID-19 outbreak: an innovative model of tiered primary health care in Taiwan. BJGP Open. 2020;4(2):bjgpopen20X101068. doi:10.3399/bjgpopen20X101068
  • Huang WT, Chen YY. The War against the Coronavirus disease (COVID-2019): keys to successfully defending Taiwan. Hu Li Za Zhi. 2020;67(3):75–83. doi:10.6224/JN.202006_67(3).10
  • The Time. What we can Learn from Singapore, Taiwan, and Hong Kong about handling Coronavirus; 2020 Available from: https://time.com/5802293/coronavirus-covid19-singapore-hong-kong-taiwan/. Accessed 87, 2020.
  • Financial Times. Containing coronavirus: lessons from Asia; 2020 Available from: https://www.ft.com/content/e015e096-6532-11ea-a6cd-df28cc3c6a68. Accessed 87, 2020.
  • Li Yang HSU, Min-Han T. What Singapore can teach the U.S. about responding to Covid-19. STAT. Available from: https://www.statnews.com/2020/03/23/singapore-teach-united-states-about-covid-19-response/. Accessed 87, 2020.
  • Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;16(6):1232–1238. doi:10.1080/21645515.2020.173522732186952
  • Schaefer GO, Tam CC, Savulescu J, Voo TC. COVID-19 vaccine development: time to consider SARS-CoV-2 challenge studies? Vaccine. 2020;38(33):5085–5088. doi:10.1016/j.vaccine.2020.06.00732540271
  • Ministry of Health, Singapore. Confirmed imported case of novel coronavirus infection in Singapore; multi-ministry taskforce ramps up precautionary measures; 1 23, 2020 Available from: https://www.moh.gov.sg/news-highlights/details/confirmed-imported-case-of-novel-coronavirus-infection-in-singapore-multi-ministry-taskforce-ramps-up-precautionary-measures. Accessed 88, 2020.
  • World Health Organization. Coronavirus disease (COVID-19) pandemic; 2020 Available from: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov. Accessed 88, 2020.
  • Lim WH, Wong WM. COVID-19: notes from the Front Line, Singapore’s primary health care perspective. Ann Fam Med. 2020;18(3):259–261. doi:10.1370/afm.253932393562
  • Taylor Vinters. Singapore – why is the city a global business hub; 2016 Available from: https://www.taylorvinters.com/article/singapore-city-global-business-hub. Accessed 88, 2020.
  • Budget Direct Insurance. Singapore Tourism Statistics, 2020. An in-depth analysis of the latest tourism statistics for Singapore; 2020 Available from: https://www.budgetdirect.com.sg/travel-insurance/research/singapore-tourism-statistics. Accessed 88, 2020.
  • Budget Direct Insurance. Medical Tourism Singapore, 2020. An in-depth analysis of Medical Tourism in Singapore. Available from: https://www.budgetdirect.com.sg/travel-insurance/research/medical-tourism-singapore. Accessed 88, 2020.
  • Lin RJ, Lee TH, Lye DC. From SARS to COVID-19: the Singapore journey. Med J Aust. 2020;212(11):497–502.e1. doi:10.5694/mja2.5062332474940
  • Dan YY, Tambyah PA, Sim J, et al. Cost-effectiveness analysis of hospital infection control response to an epidemic respiratory virus threat. Emerg Infect Dis. 2009;15(12):1909–1916. doi:10.3201/eid1512.09090219961669
  • Koh Y, Hegney D, Drury V. Nurses’ perceptions of risk from emerging respiratory infectious diseases: a Singapore study. Int J Nurs Pract. 2012;18(2):195–204. doi:10.1111/j.1440-172X.2012.02018.x22435984
  • Yang Y, Shang W, Rao X. Facing the COVID-19 outbreak: what should we know and what could we do. J Med Virol. 2020;92(6):536–537. doi:10.1002/jmv.2572032091134
  • Kunin M, Engelhard D, Piterman L, Thomas S. Response of general practitioners to infectious disease public health crises: an integrative systematic review of the literature. Disaster Med Public Health Prep. 2013;7(5):522–533. doi:10.1017/dmp.2013.8224274132
  • Kumar P. How to strengthen primary health care. J Fam Med Prim Care. 2016;5(3):543–546. doi:10.4103/2249-4863.197263
  • Haque M, Islam T, Rahman NAA, McKimm J, Abdullah A, Dhingra S. Strengthening primary health-care services to help prevent and control long-term (chronic) non-communicable diseases in low- and middle-income countries. Risk Manag Healthc Policy. 2020;13:409–426. doi:10.2147/RMHP.S23907432547272
  • Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of Coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545–1549. doi:10.1007/s11606-020-05762-w32133578
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-531986264
  • Khoo HS, Lim YW, Vrijhoef HJ. Primary healthcare system and practice characteristics in Singapore. Asia Pac Fam Med. 2014;13(1):8. doi:10.1186/s12930-014-0008-x25120380
  • Health Information Division, Ministry of Health, Singapore Primary Care Survey 2014. Available from: https://www.moh.gov.sg/docs/libraries. Accessed 88, 2020.
  • Tan Z, Khoo DWS, Zeng LA, et al. Protecting health care workers in the front line: innovation in COVID-19 pandemic. J Glob Health. 2020;10(1):010357. doi:10.7189/jogh.10.01035732509288
  • Chang CM, Tan TW, Ho TC, Chen CC, Su TH, Lin CY. COVID-19: Taiwan’s epidemiological characteristics and public and hospital responses. Peer J. 2020;8:e9360. doi:10.7717/peerj.936032551205
  • Jan CF, Chiu TY, Chen CY, Guo FR, Lee MC. A 10-year review of health care reform on Family Practice Integrated Care Project-Taiwan experience. Fam Pract. 2018;35(4):352–357. doi:10.1093/fampra/cmx11129194539
  • Lin C, Braund WE, Auerbach J, et al. Policy Decisions and Use of Information Technology to Fight COVID-19, Taiwan. Emerg Infect Dis. 2020;26(7):1506–1512. doi:10.3201/eid2607.20057432228808
  • Pulia MS, O’Brien TP, Hou PC, Schuman A, Sambursky R. Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic. Ann Med. 2020;52(5):207–214. doi:10.1080/07853890.2020.176344932370561
  • Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open-label phase II multicentre randomized controlled trial (PLACID Trial). BMJ. 2020;371:m3939. doi:10.1136/bmj.m393933093056

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.